Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hsacirc0006420 circular RNA and application thereof in glioma diagnosis and prognosis evaluation

A technology for prognostic assessment and glioma, applied in the field of cancer diagnosis, can solve the problems that the survival rate is not optimistic and the survival rate of glioma patients has not been significantly improved.

Pending Publication Date: 2022-04-05
上海纽仁生物医药科技有限公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, although the diagnosis and treatment methods of glioma are in the stage of continuous improvement, the survival rate of glioma patients has not been significantly improved.
The diagnosis of glioma is still in the empirical stage based on clinical, pathological and imaging information, and once diagnosed, most of them are in the middle and advanced stages, and the survival rate after surgery is not optimistic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hsacirc0006420 circular RNA and application thereof in glioma diagnosis and prognosis evaluation
  • Hsacirc0006420 circular RNA and application thereof in glioma diagnosis and prognosis evaluation
  • Hsacirc0006420 circular RNA and application thereof in glioma diagnosis and prognosis evaluation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Identification of embodiment 1hsa_circ_0006420

[0043] 1. RNA extraction (Trizol method)

[0044](1) Add 1ml trizol to tumor tissue and plasma;

[0045] (2) Add 200 μL of chloroform, shake vigorously for 10 seconds, and let stand at room temperature for 10 minutes;

[0046] (3) Centrifuge at 12,000g for 10min at 4°C, the solution is divided into three layers, the RNA is dissolved in the water phase, and the water phase is transferred to another new RNase free EP tube;

[0047] (4) Add 1 volume of isopropanol, vortex and mix thoroughly;

[0048] (5) Centrifuge at 12,000g for 15min at 4°C. After centrifugation, RNA precipitates at the bottom of the tube, discard the supernatant;

[0049] (6) Add 1ml of 75% ethanol, invert gently by hand, centrifuge at 12,000g for 5min, and discard the supernatant;

[0050] (7) Dry at room temperature, add 20 μL DEPC water to dissolve the precipitate.

[0051] 2. Genomic DNA Removal

[0052] To remove the residue of genomic DNA in t...

Embodiment 2

[0065] Fluorescent quantitative PCR detection of hsa_circ_0006420 for the diagnosis of glioma

[0066] The method for detecting the expression of the circular RNA hsa_circ_0006420 molecule in tissue and plasma by fluorescent quantitative PCR amplification is as follows: extract the total RNA according to the method described in Example 1, remove the remaining genomic DNA in the extracted RNA with DNase, and reverse transcribe the RNA into cDNA; finally, it is detected by fluorescent quantitative PCR amplification, and the primer sequence of fluorescent quantitative PCR is shown in SEQID NO.2-5. The size of the amplified circular hsa_circ_0006420 circularization interface region sequence is 200bp.

[0067] Fluorescent quantitative PCR amplification detection of circular RNA hsa_circ_0006420 molecule expression in tissue and plasma The reaction system and reaction conditions are as follows:

[0068] cDNA 1μL Upstream primer (10μM) 0.2 μL Downstream primer...

Embodiment 3

[0072] Fluorescent quantitative PCR detection of hsa_circ_0006420 for prediction of temozolomide treatment in glioma

[0073] Patients with glioma treated with temozolomide were enrolled, and plasma samples (5ml of blood per patient, 1.5ml of plasma collected after centrifugation and stratification) were collected in advance and stored in a -80°C refrigerator. Follow-up clinically tracked the response effect of patients to temozolomide treatment, and divided them into response group (R, response group, stable or partially stable disease) and non-response group (NR, non-response group, disease progression) according to the treatment effect. After matching the clinical baseline parameters such as age and gender to exclude the influence of other clinical parameters, 25 cases of plasma were taken from each group of the response group (R) and the non-response group (NR) for fluorescent quantitative PCR detection, and the expression of hsa_circ_0006420 in the two groups Difference c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an hsacirc0006420 circular RNA (Ribonucleic Acid) and application of the hsacirc0006420 circular RNA in glioma diagnosis and prognosis evaluation, and belongs to the field of cancer diagnosis. The nucleotide sequence of the hsacirc0006420 circular RNA is as shown in SEQ ID NO. 1 (sequence identifier number 1). According to the present invention, the new hsacirc0006420 circular RNA gene is obtained, the expression of the hsacirc0006420 circular RNA in the glioma tumor tissue and the patient blood sample is significantly increased, and the new hsacirc0006420 circular RNA gene can be used for the glioma diagnosis, the response after the temozolomide treatment, and the patient lifetime prediction.

Description

technical field [0001] The invention belongs to the technical field of cancer diagnosis, and in particular relates to a hsa_circ_0006420 circular RNA and its application in glioma diagnosis and prognosis assessment. Background technique [0002] Glioma is the most frequent brain tumor in adults, accounting for 40.49% of intracranial tumors. From the time of diagnosis, the average life expectancy of patients with glioma is less than five years. At present, although the diagnosis and treatment methods of glioma are in the stage of continuous improvement, the survival rate of glioma patients has not improved significantly. The diagnosis of glioma is still in the empirical stage based on clinical, pathological and imaging information, and once diagnosed, most of them are in the middle and advanced stages, and the survival rate after surgery is not optimistic. Therefore, it is an urgent research task in the field of neuroscience to find early diagnostic markers for glioma to "e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113C12N15/11C12Q1/6886C12Q1/6851
Inventor 张允斌张倩
Owner 上海纽仁生物医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com